New lung cancer pill hailed as ‘off the charts’ success – with patients surviving years longer than those on next best treatment

Around six in ten patients given the daily tablet treated with lorlatinib survived for five years without their cancer progressing, compared to just eight per cent receiving standard care.Around six in ten patients given the daily tablet treated with lorlatinib survived for five years without their cancer progressing, compared to just eight per cent receiving standard care.Read MoreHealth News | Mail Online